President and CEO
Mark Bamforth is President and CEO of Arranta Bio, a CDMO providing services to drug companies working on new therapies targeting diseases linked to the human microbiome. Prior to founding Arranta Bio in 2019, he was President and CEO of Brammer Bio, a cell and gene therapy CDMO, which was acquired by Thermo Fisher Scientific for $1.7 billion in 2019. Previously, he founded Gallus BioPharmaceuticals, a biologics CDMO, which was acquired by DPx Holdings B.V., the parent company of Patheon, in 2014.
Prior to his founding of Brammer Bio and Gallus BioPharmaceuticals, Mr. Bamforth spent 22 years with Genzyme Corporation (now part of Sanofi), rising to the position of Senior Vice President of Corporate Operations and Pharmaceuticals. In this role, he oversaw a multi-technology, global operations team comprising more than 3,600 individuals at 13 internal sites and a network of 24 contract manufacturing organizations. This team was charged with supplying over 20 commercial products and multiple clinical products that spanned biologics, cell therapy, gene therapy, pharmaceuticals and biologic devices. While at Genzyme, Mr. Bamforth served as a member of the CEO’s Operating Committee and helped guide corporate strategy acquisition, partnering and growth to more than $4 billion in sales.
Mr. Bamforth also serves on the boards of MassBio and the Wentworth Institute of Technology and is a Saltire Foundation founding trustee. He earned a Bachelor of Science in chemical engineering from Strathclyde University and a Master of Business Administration from Henley Management College.